Prevalence of metabolic dysfunction–associated fatty liver disease among patients with diabetic kidney disease: a systematic review and meta-analysis
Open Access
- 2 December 2024
- journal article
- review article
- Published by Springer Nature in Egyptian Liver Journal
- Vol. 14 (1) , 1-9
Abstract
Background: Mechanistic relationships between metabolic dysfunction–associated fatty liver disease (MAFLD) and chronic kidney disease are well characterized. Specifically, in type 2 diabetes (T2D), insulin resistance leads to MAFLD, and hyperglycemia leads to microvascular complications such as diabetic kidney disease (DKD). This systematic review and meta-analysis aims to describe the specific association between MAFLD and DKD for the first time. Methods: PubMed, Web of Science, Google Scholar, and Scopus databases were searched up to February 2023 to identify relevant published articles. After screening the titles, abstracts, and full texts of the retrieved articles, cross-sectional studies and cohorts reporting on MAFLD in patients with DKD were identified and then analyzed. Results: A total of 2615 articles were identified, of which 5 had sufficient data and fulfilled the eligibility criteria for meta-analysis. A total of 2345 patients with DKD were in the included studies. The prevalence rates of radiologically diagnosed MAFLD among patients with DKD ranged from 25 to 96%. The pooled prevalence rate of radiologically diagnosed MAFLD among patients with DKD was 0.55 (95% CI = 0.21–0.89, I2 = 99.79%, P-value < 0.01). Conclusion: MAFLD is prevalent in patients with DKD. This finding emphasizes the need for aggressive case finding and then guideline-directed medical therapy of MAFLD, especially in patients with T2D and DKD to prevent further complications. Future studies should investigate mechanisms underpinning MAFLD and DKD in patients with T2D, especially in the context of cardiometabolic risk.Keywords
This publication has 61 references indexed in Scilit:
- Metabolic dysfunction–associated fatty liver disease (MAFLD): an update of the recent advances in pharmacological treatmentJournal of Physiology and Biochemistry, 2023
- Associations of non-invasive indices of liver steatosis and fibrosis with progressive kidney impairment in adults with type 2 diabetesActa Diabetologica, 2023
- Metabolic dysfunction-associated fatty liver disease can significantly increase the risk of chronic kidney disease in adults with type 2 diabetesDiabetes Research and Clinical Practice, 2023
- Comorbidities Are Associated with Fibrosis in NAFLD Subjects: A Nationwide Study (NASH-CO Study)Digestive Diseases and Sciences, 2021
- Screening for non-alcoholic fatty liver disease using liver stiffness measurement and its association with chronic kidney disease and cardiovascular complications in patients with type 2 diabetesDiabetes & Metabolism, 2020
- METTL14 suppresses the metastatic potential of hepatocellular carcinoma by modulating N 6‐methyladenosine‐dependent primary MicroRNA processingHepatology, 2016
- The economic and clinical burden of nonalcoholic fatty liver disease in the United States and EuropeHepatology, 2016
- Association between non-alcoholic fatty liver disease and chronic kidney disease in population with prediabetes or diabetesInternational Urology and Nephrology, 2014
- Albuminuria and insulin resistance in children with biopsy proven non-alcoholic fatty liver diseasePediatric Nephrology, 2009
- Non-alcoholic fatty liver disease is independently associated with an increased prevalence of chronic kidney disease and proliferative/laser-treated retinopathy in type 2 diabetic patientsDiabetologia, 2007